FRAILTY ASSESSMENT AS PREDICTOR OF BLEEDING FOR PATIENTS TREATED WITH ACALABRUTINIB
Introduction: The American Society of Clinical Oncology (ASCO) promotes the routine use of a comprehensive geriatric assessment, particularly emphasizing frailty, to identify vulnerabilities not detected in the standard clinical evaluation. However, frailty remains an under-explored topic in Chronic...
Main Authors: | TX Carneiro, JLS Sales, JS Tavares, IJM Wanderley, JKD Santos, LBC Leão, LDS Pimentel, NS Moraes |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923005631 |
Similar Items
-
FRAILTY ASSESSMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE COMBINATION OF VENETOCLAX AND IBRUTINIB
by: TX Carneiro, et al.
Published: (2023-10-01) -
SAFETY OF DARATUMUMAB IN FRAIL PATIENTS WITH MULTIPLE MYELOMA
by: TX Carneiro, et al.
Published: (2023-10-01) -
FRAILTY ASSESSMENT IN PATIENTS WITH LYMPHOMA.
by: TX Carneiro, et al.
Published: (2023-10-01) -
PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: T. Byalik, et al.
Published: (2022-06-01) -
PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
by: Tatyana Byalik, et al.
Published: (2023-08-01)